**************************************************************

MusclePharm Corporation (OTCBB:MSLP), one of the fastest growing nutritional supplement companies in the United States with a proprietary formulation used in eight performance products, appointed Mariel Selbovitz, MPH, as Director of Global Therapeutics Product Procurement Development.

“We are thrilled to have Ms. Selbovitz join the MusclePharm team as we enter the therapeutic, nutritional supplementation market that is focused on products to meet the nutritional requirements of people living with HIV/AIDS,” stated Cory Gregory, MusclePharm’s President. “MusclePharm is working to greatly expand our sales of therapeutic, nutritional supplementation and provide increased help to people in need across the globe.”

Mr. Gregory continued, “We believe Ms. Selbovitz expertise and experience in the field of HIV will assist us secure distribution of MusclePharm products, such as Recon, to people living with the HIV disease in developing nations thru The Global Fund to Fight AIDS, Tuberculosis and Malaria, and The Presidents Emergency Plan for AIDS Relief (PEPFAR).”

The Global Fund to Fight AIDS, Tuberculosis and Malaria is an international financing institution that invests the world’s money to battle disease. To date, it has committed US$19.3 billion in 144 countries to support large-scale prevention, treatment and care programs against these three diseases.

“With Ms. Selbovitz extensive experience and assistance we plan to reach millions of people living with HIV in developing nations,” stated Dr. Roscoe Moore, former United States Surgeon General, and Chief Science Director for MusclePharm. “Participating in programs such as the Global Fund and PEPFAR and will enable MusclePharm to help counteract some of the devastating effects of HIV related nutritional deficiencies which greatly affect the immune system, as well as the growth and retention of muscle mass.”

Power3 Medical Products, Inc. (OTC.BB:PWRM), a leading proteomics company focused on the development of innovative diagnostic tests in the fields of cancer and neurodegenerative diseases, announced today that it has signed a definitive agreement to acquire all of the stock of Rozetta-Cell Life Sciences, Inc. Power3 plans to effectuate the acquisition of Rozetta-Cell by merging Rozetta-Cell with and into Power3, with Power3 remaining as the surviving company in the merger. The acquisition of Rozetta-Cell is expected to be completed in October or November 2010.

Rozetta-Cell is a medical biotechnology company that focuses on the delivery and imaging of stem cells during therapy. The company has a robust intellectual property portfolio and has created numerous products for adult stem cell therapy that are ready for market globally. Rozetta-Cell also has several collaborations in process through which it is partnering with industry-leading adult stem cell research companies and adult stem cell vendors.

“We are very excited to be acquiring Rozetta-Cell Life Sciences,” stated Ira L. Goldknopf, President and Chief Scientific Officer of Power3 Medical Products, Inc. “Rozetta-Cell brings us a tremendous amount of complementary adult stem cell therapy technology, know-how and experience. With the addition of Rozetta-Cell, Power3 will significantly strengthen its IP portfolio in a major growth market by merging regenerative medicine with the technologies that we are using to identify disease-specific protein biomarkers and develop them into screening and diagnostic tests to address unmet medical needs.”

Forrester Research, Inc., (Nasdaq: FORR) will host three new role-focused Forums, furthering the company’s commitment to serving IT, marketing, and technology industry professionals through a role-based strategy. Forrester’s CIO Forum, Business Process & Application Delivery Forum, and Content & Collaboration Forum will take place October 7-8, 2010 at Gaylord National Resort & Convention Center in Washington, D.C.

“Role-based events are just one of the ways in which Forrester is positioned to address the unique challenges IT professionals face when trying to balance their day-to-day job with staying in front of the next big wave of technology change,” said Julie Meringer, managing director of Forrester’s IT client group. “Our focus on business technology enables attendees to capitalize on these changes and radically rethink the way they implement and manage IT.”

Forrester Research, Inc. is an independent research company that provides pragmatic and forward-thinking advice to global leaders in business and technology. Forrester works with professionals in 19 key roles at major companies providing proprietary research, customer insight, consulting, events, and peer-to-peer executive programs. For more than 27 years, Forrester has been making IT, marketing, and technology industry leaders successful every day.

**************************************************************

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. DrStockPick.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold DrStockPick.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at http://drstockpick.com/disclaimer) .Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings, Inc. (CRWE.OB) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings Inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period.

Crown Equity Holdings Inc. (CRWE.OB) has previously received five hundred thousand shares compensation for 30 days of advertisement services and received an additional 1,000,000 shares 144 restricted stocks for a continuation of 6 months of advertisement and disseminating news, as well as $15,000 dollars for IR services for Power 3 Medical Products Inc. (PWRM.OB). Recently, Crown Equity Holdings, Inc has received an additional amount of 2,000,000 shares of free trading stock for 60 days media advertisement, web design and maintenance for Power 3 Medical Products Inc. (PWRM.OB)

Crown Equity Holdings Inc. (CRWE.OB) has received twenty five thousand dollars in cash and seventy five thousand free trading shares from a third party (Bishop Equity Partners) for (30) days of advertising for Muscle Pharm Corp.(MSLP.OB).

**************************************************************

Power 3 Medical Products Inc. (PWRM.OB), strives to become the premier biotechnology company specializing in the commercialization of proteomics IP for the diagnosis and treatment of disease by using cutting edge technologies, world class quality procedures and superior research methodologies. PWRM will be guided in all of its dealings with its customers, partners, shareholders, associates and investors by the philosophy of best practices.

PWRM, a bio-technology company, engages in the development and marketing of diagnostic tests in the fields of cancer, neurodegenerative and neuromuscular diseases in the United States. PWRM’s products include BC-SeraPro, a proteomic blood serum test for the early detection of breast cancer; and NuroPro, a serum test for the detection of neurodegenerative diseases, such as amyotrophic lateral sclerosis, Alzheimer’s disease, and Parkinson’s disease. PWRM’s products analyze proteins and their mutations to assess an individuals risk for developing disease later in life or a patient’s likelihood of responding to a particular drug; assess a patient’s risk of disease progression and disease recurrence; and measure a patient’s exposure to drug therapy. PWRM was formerly known as Surgical Safety Products, Inc. and changed its name to Power3 Medical Products, Inc. in September 2003. PWRM was founded in 1992 & is based in The Woodlands, Texas.

Gold American Mining Corp. (OTC.BB:SILA) has received the final ground geophysics report on its Guadalupe property and confirms that the recently concluded geophysics program has identified multiple potentially significant geophysical anomalies.

The geophysical survey was designed to test down to depths of 500 metres. The key results from the geophysics program are:

* Magnetic susceptibility survey was successful in identifying the trace near the surface extensions of the known veins. The presence of additional parallel anomalies suggests the potential for additional veins that do not outcrop.
* Induced Polarization anomalies indicate the potential for down dip extensions to the main veins within the property.
* A potentially significant chargeability anomaly (Induced Polarization) occurs in the southern portion of the property in between the Santa Rosa and San Antonio Mines at depth starting at 400 m, which is below the known depth of these historically important mines.

“The final results and interpretation of the geophysics results on our Guadalupe property have given us very attractive drilling targets. We are in the process of acquiring firm bids from several qualified drilling contractors and initiating the permitting process for the next phase of exploration of this exciting project,” commented Johannes Petersen, President of Gold American. “Gold American is well on track to initiating drilling operations on Guadalupe during the fourth quarter of 2010,” added Mr. Petersen.

American Power Corp. (OTC.BB:TGMP) has retained Weir International Inc. of Downers Grove, Illinois (”Weir”) to prepare an exploration drilling program and to supervise the execution of that program, in order to evaluate the coal reserve potential on the Pace coal property in Judith Basin County, Montana.

Weir is an internationally recognized consulting firm that has provided engineering consulting services to the American and international mining and energy industries for over 75 years. Weir has prepared coal reserve reports for several established mining companies including BHP Billiton, the world’s largest mining company by market cap at $183bn, among many other major coal producers including Arch Coal Inc., publicly traded on the NYSE, and America’s second largest coal producer.

American Power Corp. is a publicly traded, dynamic energy company based in Denver, Colorado. The Company was established with the focus of acquiring near-term, large-scale coal projects in close proximity to national transportation links. American Power envisions developing its large coal resources to support electricity generation.

Motorola Inc. (NYSE: MOT) intends to invest $3.5 billion into its mobile-phone and set-top box units that will be spun off in the first quarter of fiscal 2011. A lot of this money comes from activist billionaire Carl Ichan who continues to plow money into Motorola as the company prepares to split off its mobile-phone and set-top box unit into a new company.

Icahn bought about 14.8 million shares in the communications-device maker between Aug. 26 and Tuesday for $111 million, or about $7.50 per share. Icahn now owns about 250 million Motorola shares, or a 10.7% stake.

The money will be used to manage and build the business and make acquisitions. The Motorola Mobility unit is applying for a separate listing on the New York Stock Exchange. Motorola’s spin-off has been in progress since early 2008. The company decided to split its Mobile Devices and Home Division as Motorola Mobility and the Enterprise Mobility Solutions and Networks businesses as Motorola Solutions.

Although Motorola shows a huge sequential growth of its 3G smartphones, in absolute terms, the 2.7 million device shipment is far behind other leading manufacturers, and is not anticipated to reach the lofty numbers of other smart phone makers. After the success of Droid, Motorola launched Droid 2, which is an enhanced version of Droid and Droid X with double the speed and memory of the original Droid phone.

Apple Inc. (NASDAQ:AAPL) presents a smaller, cheaper version of its Apple TV device for streaming movies and television shows over the Internet and into the living room.

The tiny new Apple TV system will only let people rent, not buy, content. For first-run high-definition movies the day they come out on DVD, people will have to pay $4.99. High-definition TV show rentals will be 99 cents.

The price of the box is also being cut to $99, from $229. Cheaper options for streaming video had been available, including Roku’s set-top boxes that start at $60.

Apple TV has been around since 2007, but it hasn’t caught on with the mainstream. For one thing, it doesn’t record shows the way TiVo and other digital video recorders do. And the need to sync the box with a computer was too complicated for most consumers, Apple CEO Steve Jobs said.

The new Apple TV, which will be available within a month, will give people access to the high-definition version of top movies, though Jobs didn’t say which movie studios have agreed to include their titles for streaming. People who watch content from Netflix Inc. streamed over the Internet can also access their “instant” queue through AppleTV.

Some media companies have raised concerns that the 99-cent television rentals would undercut higher-priced offerings for permanent download, which sell for $1.99 and $2.99.

**************************************************************

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. DrStockPick.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold DrStockPick.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at http://drstockpick.com/disclaimer) .Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings, Inc. (CRWE.OB) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings Inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period.

Crown Equity Holdings Inc. (CRWE.OB) has previously received five hundred thousand shares compensation for 30 days of advertisement services and received an additional 1,000,000 shares 144 restricted stocks for a continuation of 6 months of advertisement and disseminating news, as well as $15,000 dollars for IR services for Power 3 Medical Products Inc. (PWRM.OB). Recently, Crown Equity Holdings, Inc has received an additional amount of 2,000,000 shares of free trading stock for 60 days media advertisement, web design and maintenance for Power 3 Medical Products Inc. (PWRM.OB)

Crown Equity Holdings, Inc. (CRWE.OB) has received twenty-five thousand dollars in cash from a third party (Winning Media) for (3) days of advertising for Gold American Mining Corp (SILA.OB)

Crown Equity Holdings Inc. (CRWE.OB) has received Eight thousand dollars from a third party (Winning Media) for on (1) day of advertising for AMERICAN POWER CORP (OTC BB: TGMP.OB)

**************************************************************

PROTEONOMIX, INC. (OTC.BB:PROT), a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives, reports that Mr. Michael Cohen, Chairman and CEO, is scheduling a multi-city European road trip to create additional awareness of the Proteonomix, Inc. investment opportunity to institutional investors.

Scheduled for early October, Mr. Cohen will discuss with sophisticated investors the recent contract to establish a joint venture with a group of investors that will establish a new stem cell treatment and research facility in the United Arab Emirates (U.A.E.). In addition, Mr. Cohen will discuss the opportunity to set up additional joint ventures in other countries using the U.A.E. arrangement as a model.

The recent contract calls for the joint venture partner to invest $5 million on or before September 10, 2010 in a Joint Venture company, XGEN Medical LLC. (”XGen”), a Nevis Island limited liability company.

“Proteonomix has made great strides recently,” stated Mr. Cohen, “and we have been contacted by several European entities that have requested additional information about our proprietary stem cell activities. In recognition of the interest in Europe and the potential for additional joint venture agreements in various European countries, we recognize that it is propitious to meet with a number of the European institutional investors both to educate them on the intrinsic value of Proteonomix shares and garner interest in strategic relationships.”

Power 3 Medical Products Inc. (PWRM.OB), strives to become the premier biotechnology company specializing in the commercialization of proteomics IP for the diagnosis and treatment of disease by using cutting edge technologies, world class quality procedures and superior research methodologies. PWRM will be guided in all of its dealings with its customers, partners, shareholders, associates and investors by the philosophy of best practices.

PWRM, a bio-technology company, engages in the development and marketing of diagnostic tests in the fields of cancer, neurodegenerative and neuromuscular diseases in the United States. PWRM’s products include BC-SeraPro, a proteomic blood serum test for the early detection of breast cancer; and NuroPro, a serum test for the detection of neurodegenerative diseases, such as amyotrophic lateral sclerosis, Alzheimer’s disease, and Parkinson’s disease. PWRM’s products analyze proteins and their mutations to assess an individuals risk for developing disease later in life or a patient’s likelihood of responding to a particular drug; assess a patient’s risk of disease progression and disease recurrence; and measure a patient’s exposure to drug therapy. PWRM was formerly known as Surgical Safety Products, Inc. and changed its name to Power3 Medical Products, Inc. in September 2003. PWRM was founded in 1992 & is based in The Woodlands, Texas.

Bioanalytical Systems, Inc. (NASDAQ:BASI) reports that Alberto Hidalgo has joined the Company as Vice President - Business Development and Marketing. Mr. Hidalgo has over 15 years of senior-level sales experience in both domestic and international markets including 13 years in the CRO Market. Most recently he consulted with companies to develop and implement new sales and marketing strategies. Prior to that he served as Area Director of Sales with Covance Central Laboratory Services and held various positions including Director of Sales, for Eli Lilly Export, Puerto Rico. He has a strong history of developing new business relationships and sales strategies resulting in exceptional sales growth.

On August 18, 2010, the Company granted Mr. Hidalgo a non-qualified stock option to purchase 30,000 shares of common stock of the Company as an inducement to his employment. The exercise price of the option is $1.00 per share. The option becomes exercisable in four equal annual installments beginning on August 18, 2012. The option vesting schedule is subject to acceleration upon a change of control. The number of shares exercisable by the option is subject to a proportional adjustment upon a capitalization event. The option will expire on August 18, 2020, unless terminated sooner based upon Mr. Hidalgo’s cessation of service with the Company.

BASi is a pharmaceutical development company providing contract research services and research instruments and supplies to the world’s leading drug development companies and medical research organizations. The company focuses on developing innovative services and products that increase efficiency and reduce the cost of taking a new drug to market.

**************************************************************

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. DrStockPick.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold DrStockPick.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at http://drstockpick.com/disclaimer) .Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings, Inc. (CRWE.OB) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings Inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period.

Crown Equity Holdings Inc. (CRWE.OB) has received twenty thousand dollars in cash and twenty thousand dollars in free trading shares from a third party (Swiss Financial Report) for (30) days of advertisement services for Proteonomix, Inc. (PROT.OB)

Crown Equity Holdings Inc. (CRWE.OB) has previously received five hundred thousand shares compensation for 30 days of advertisement services and received an additional 1,000,000 shares 144 restricted stocks for a continuation of 6 months of advertisement and disseminating news, as well as $15,000 dollars for IR services for Power 3 Medical Products Inc. (PWRM.OB). Recently, Crown Equity Holdings, Inc has received an additional amount of 2,000,000 shares of free trading stock for 60 days media advertisement, web design and maintenance for Power 3 Medical Products Inc. (PWRM.OB)